Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP
Tonix Pharmaceuticals — Q3 2026 Earnings Presentation
19 slides from Tonix Pharmaceuticals's earnings presentation, Nov 9, 2026
Slide 1: Third Quarter 2026 Financial Results and Operational Highlights
Third Quarter 2026 Financial Results and Operational Highlights Third Quarter 2026 Financial Results and Operational Highlights NOVEMBER 9, 2026 NASDAQ: TNXP PO6170 November 9, 2026 1687 © 2026 Tonix Pharmaceuticals Holding Corp. © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 2: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements Cautionary Note on Forward-Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the Company’s expected financial performance,
Slide 3: Tonix's Third Quarter 2026 Earnings Call
Tonix’s Third Quarter 2026 Earnings Call Tonix’s Third Quarter 2026 Earnings Call TONMYA Growth and Priority Clinical Programs • ~$15 million in net sales in 3Q’26 (37% QoQ growth) TONMYA Launch • Key metrics grew following the September 1 sales force expansion • ~53% of U.S. covered lives (166 mill
Slide 4: Strong TONMYA Performance in the Third Quarter
Strong TONMYA Performance in the Third Quarter Net sales and prescription metrics increased quarter-over-quarter 3Q Net Sales 3Q Key Metrics QoQ Growth ~$15M Prescriptions 28% 16,375 New 17% 37% Prescriptions Growth over Q2’26 Refills 56% Key metrics grew following the September 1 sales force expans
Slide 5: TONMYA Access, Awareness, and Engagement Is Growing
TONMYA Access, Awareness, and Engagement Is Growing TONMYA Access, Awareness, and Engagement Is Growing Third Quarter and Recent Highlights Market Access Marketing Medical Affairs • 53% of total U.S. covered • Encouraging market • KOL engagement and lives (166M lives) research of top education • 2 G
Slide 6: TNX-102 SL to Treat MDD: Targeting Disturbed Sleep
TNX-102 SL1 to Treat MDD: Targeting Disturbed Sleep Phase 2, potentially pivotal study The Opportunity Study Design Study Status • Patients: Target enrollment of ~360 21M+ • Enrolling: U.S. adults aged 18+ experiencing a moderate to severe major - HORIZON enrollment ongoing Adults in the U.S. depres
Slide 7: TNX-4800 Adaptive Phase 2 TRAIL Field Study: Expected Enrollment Timing
TNX-48001 Adaptive Phase 2 TRAIL Field Study: Expected Enrollment Timing Long-acting, human monoclonal antibody targeting OspA of Borrelia burgdorferi, engineered for an extended half-life Lead-in Cohort: Safety and Efficacy Remaining Cohort: Efficacy Upcoming Milestones • Expected to begin in 2028,
Slide 8: TNX-4800 Adaptive Phase 2 TRAIL Field Study Recruitment Profile
TNX-4800 Adaptive Phase 2 TRAIL Field Study Recruitment Profile Lifestyle Frequently involved in occupational or recreational outdoor activities and/or has repeated exposure to wooded, grassy, or tick- prone environments Endemic Areas Risk Perception Resides, works, or regularly travels to Lyme- Pro
Slide 9: TNX-4800 Has a Significant Opportunity: Market Research Findings
TNX-4800 Has a Significant Opportunity: Market Research Findings Surveyed primary care providers and key opinion leaders most often cited preventive therapies as an unmet need Provider and Payer Respondents’ Feedback: • People are highly aware and concerned about the THE OPPORTUNITY threat of Lyme d
Slide 10: TNX-1500 (mosdaprubart): Anti-CD40L for Prevention of Kidney Transplant Rejection
TNX-1500 (mosdaprubart)1: Anti-CD40L for Prevention of Kidney Transplant Rejection Phase 2 investigator-initiated study at Massachusetts General Hospital (MGH) The Opportunity Study Design3 Upcoming Milestone • Design: Open-label, single-arm study • CNIs, today's standard of care, prevent led by MGH
Slide 11: Financial Highlights
Financial Highlights TONMYA NET REVENUE ZEMBRACE SYMTOUCH, TOTAL NET REVENUE TOSYMRA NET REVENUE $15M + $2.2M = $17.2M Third quarter 2026 Third quarter 2026 Third quarter 2026 CASH & EQUIVALENTS $163M As of September 30, 2026, with no debt For additional financial information, see the Company’s thir
Slide 12: TONMYA Growth and Clinical Development Priorities
TONMYA Growth and Clinical Development Priorities Business Priorities Grow the Advance priority Support TONMYA clinical programs sustainable business growth and TNX-102 SL (MDD); TNX-4800 (Lyme prevention); TNX-1500 (prevention of shareholder value kidney transplant rejection) 12 © 2026 Tonix Pharma
Slide 13: Thank you
Thank you Thank you 10 © 2026 Tonix Pharmaceuticals Holding Corp. © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 14: TONMYA Important Safety Information (1 of 2)
TONMYA® (cyclobenzaprine hydrochloride sublingual tablets) INDICATION: TONMYA is indicated for the treatment of fibromyalgia in adults. Important Safety Information (1 of 2) IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TONMYA is contraindicated: In patients with hypersensitivity to cyclobenzaprine
Slide 15: TONMYA Important Safety Information (2 of 2)
TONMYA® (cyclobenzaprine hydrochloride sublingual tablets) INDICATION: TONMYA is indicated for the treatment of fibromyalgia in adults. Important Safety Information (2 of 2) IMPORTANT SAFETY INFORMATION (CONT’D) ADVERSE REACTIONS The most common adverse reactions (incidence ≥2% and at a higher incid
Slide 16: ZEMBRACE Important Safety Information (1 of 2)
ZEMBRACE® Important Safety Information (1 of 2) ZEMBRACE® Important Safety Information (1 of 2) ZEMBRACE SymTouch (ZEMBRACE) can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart atta
Slide 17: ZEMBRACE Important Safety Information (2 of 2)
ZEMBRACE® Important Safety Information (2 of 2) ZEMBRACE® Important Safety Information (2 of 2) ZEMBRACE may cause serious side effects including: • Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, const
Slide 18: TOSYMRA Important Safety Information (1 of 2)
TOSYMRA® Important Safety Information (1 of 2) TOSYMRA® Important Safety Information (1 of 2) TOSYMRA® can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop TOSYMRA and get emergency medical help if you have any signs of heart attack: • Discom
Slide 19: TOSYMRA Important Safety Information (2 of 2)
TOSYMRA® Important Safety Information (2 of 2) TOSYMRA® Important Safety Information (2 of 2) TOSYMRA may cause serious side effects including: • Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipa
Tonix Pharmaceuticals Holding — Q3 2026 Earnings Presentation on 6ix